However, treatment with BRAF and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors is only approved in patients with BRAF V600-positive melanoma, and patients with K601E-mutated melanoma do not have access to such drugs.<h4>Case presentation</h4>A female patient was diagnosed with high tumor burden metastatic melanoma harboring the BRAF K601E mutation. Here, MAP2K7 is linked to neoplasm.